The von Hippel-Lindau tumor suppressor gene (VHL) has a critical role in the pathogenesis of
clear-cell renal cell carcinoma (RCC), as VHL mutations have been found in both
von Hippel-Lindau disease-associated and sporadic RCCs. Recent studies suggest that
vascular endothelial growth factor (
VEGF)
mRNA is upregulated in RCC- and
von Hippel-Lindau disease-associated
tumors. We have therefore assessed the effect of the VHL gene product on
VEGF expression.
VEGF promoter-
luciferase constructs were transiently cotransfected with a wild-type VHL (wt-VHL) vector in several cell lines, including 293 embryonic kidney and RCC cell lines. wt-VHL
protein inhibited
VEGF promoter activity in a dose-dependent manner up to 5- to 10-fold. Deletion analysis defined a 144-bp region of the
VEGF promoter necessary for VHL repression. This VHL-responsive
element is GC rich and specifically binds the
transcription factor Sp1 in crude nuclear extracts. In Drosophila cells, cotransfected VHL represses Sp1-mediated activation but not basal activity of the
VEGF promoter. We next demonstrated in coimmunoprecipitates that VHL and Sp1 were part of the same complex and, by using a
glutathione-S-transferase-VHL fusion
protein and purified Sp1, that VHL and Sp1 directly interact. Furthermore, endogenous
VEGF mRNA levels were suppressed in permanent RCC cell lines expressing wt-VHL, and nuclear run-on studies indicated that VHL regulation of
VEGF occurs at least partly at the transcriptional level. These observations support a new mechanism for VHL-mediated transcriptional repression via a direct inhibitory action on Sp1 and suggest that loss of Sp1 inhibition may be important in the pathogenesis of
von Hippel-Lindau disease and RCC.